We Are the Frontier

Private Equity Buys Biomark Microfluidics Unit

ARCHIMED's completed purchase makes Biomark Scientific an independent genomics-tools company under new ownership.

Updated on Nov. 3, 2026 in Biotech

Bold flat-color editorial illustration of a single rectangular microfluidic chip with parallel etched channels and small chambers on a navy and cream field.
ARCHIMED completed its purchase of Standard BioTools' Microfluidics Business on November 3, which now operates as the independent genomics-tools company Biomark Scientific. AI Illustration. Upload story photo >

Live Poll

Do you trust private equity firms to keep up quality when they buy science companies?

ARCHIMED, a healthcare-focused private equity firm, completed its acquisition of Standard BioTools' Microfluidics Business on November 3, 2026. The acquired business now operates as a standalone company, Biomark Scientific, and this is a completed corporate transaction rather than a research-stage or announced product.

Why it matters

Biomark Scientific makes microfluidics tools for high-throughput and multi-assay genomics, a segment previously held inside Fluidigm before the 2022 rename to Standard BioTools. The change of ownership shows private equity capital moving into genomics tooling, a sector where instrument vendors compete on automation and throughput.

The Biomark X9 is an automated system for PCR, qPCR and NGS library preparation, workflows used to amplify and prepare DNA for analysis. The source does not provide performance benchmarks or comparisons against prior systems.

The players

ARCHIMED

A healthcare-focused private equity firm managing €15 billion across funds in Europe, North America and Asia.

Biomark Scientific

A microfluidics tools provider specializing in high-throughput and multi-assay genomics systems, including the Biomark X9.

Standard BioTools

The Nasdaq-listed life sciences tools company formerly known as Fluidigm, which sold its Microfluidics Business to ARCHIMED.

The details

Microfluidics refers to technology that manipulates very small volumes of liquid through channels etched at micrometer scale, which lets many reactions run in parallel on a single chip. Biomark Scientific's products are built on this approach for genomics workflows, including the Biomark X9, an automated platform for PCR (polymerase chain reaction, a method that copies specific DNA segments) and NGS (next-generation sequencing) library prep. The business has been run as an independent entity with the same team, now supported by ARCHIMED's resources.

Timeline

  1. 2022: Fluidigm, founded in 1999, was renamed Standard BioTools.

  2. March 16, 2026: Standard BioTools filed its Form 10-K with the SEC.

  3. October 21, 2026: The SEC declared the Form S-4 registration statement effective.

  4. November 3, 2026: ARCHIMED completed the acquisition and the business was renamed Biomark Scientific.

The Tech Race

The Biomark line traces to Fluidigm's 1999 founding, and its microfluidics platform now moves from Standard BioTools to a new owner under the Biomark Scientific name. The source does not place the business against specific named competitors or roadmap milestones.

Laboratories that use the Biomark X9 for PCR, qPCR and NGS library prep will now deal with Biomark Scientific as their vendor. The source does not state any change to pricing, support contracts or product availability.

The takeaway

Private equity ownership of genomics tools is now a live model, with Biomark Scientific operating under ARCHIMED's backing from November 3, 2026. Watch for the company's first product or capability announcements under the new name to see whether the stated plans to expand capabilities materialize.

Further reading

For broader context on the instrument makers and platforms in this space, see more Biotech coverage in our archive.

More information

Investor materials on the transaction are posted on the Standard BioTools investor relations website.

Source note: This article includes information reported by The Manila times.

Live Poll

Do you trust private equity firms to keep up quality when they buy science companies?